Estimaciones de analistas de Wall Street para Galectin Therapeutics Inc. (GALT): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 9 |
| Mantener | 2 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 11 |
| Calificación media (1-5) | 0.82 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-0.05 | ||
| 2026-08-14 | $-0.14 | $-0.09 | -55.6% |
| 2026-05-15 | $-0.08 | $-0.06 | -33.3% |
| 2026-03-31 | $-0.08 | $-0.10 | +20.0% |
| 2025-11-14 | $-0.13 | $-0.11 | -18.2% |
| 2025-08-14 | $-0.12 | $-0.16 | +25.0% |
| 2025-05-15 | $-0.15 | $-0.20 | +25.0% |
| 2025-03-31 | $-0.19 | $-0.16 | -18.8% |
Ratios de valoración
| Precio / Valor contable | -1.79 |
| EV / EBITDA | -16.28 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $7000 | $1000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$7000 | -$1000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $15.3M | $11.7M | $6.5M | $7.5M | $18.0M | $23.8M | $31.7M | $32.1M | $36.6M | $14.3M |
| Generales y Administrativos | $6.2M | $4.5M | $7.1M | $6.0M | $5.5M | $6.4M | $6.6M | $5.9M | $5.9M | $5.8M |
| Gastos Operativos | $21.5M | $16.2M | $13.6M | $13.4M | $23.4M | $30.2M | $38.4M | $38.1M | $42.4M | $20.1M |
| Beneficio Operativo | -$21.5M | -$16.2M | -$13.6M | -$13.4M | -$23.4M | -$30.2M | -$38.4M | -$38.1M | -$42.4M | -$20.1M |
| EBITDA | -$21.5M | -$16.2M | -$13.6M | -$13.2M | -$23.3M | -$30.0M | -$37.7M | -$38.2M | -$41.5M | -$23.5M |
| Gastos por Intereses | 0 | $12000 | $336000 | $87000 | $87000 | $489000 | $1.0M | $2.8M | $5.5M | $7.3M |
| Beneficio Antes de Impuestos | -$21.4M | -$16.2M | -$13.9M | -$13.3M | -$23.5M | -$30.5M | -$38.8M | -$41.1M | -$47.0M | -$30.8M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$21.4M | -$16.2M | -$13.9M | -$13.3M | -$23.5M | -$30.5M | -$38.8M | -$41.1M | -$47.0M | -$30.8M |
| BPA | $-0.73 | $-0.46 | $-0.35 | $-0.39 | $-0.41 | $-0.52 | $-0.65 | $-0.74 | $-0.76 | $-0.48 |
| BPA Diluido | $-0.73 | $-0.46 | $-0.35 | $-0.39 | $-0.41 | $-0.52 | $-0.65 | $-0.74 | $-0.76 | $-0.48 |
| Acciones en Circulación (Diluidas) | $29.2M | $35.5M | $39.4M | $52.2M | $57.0M | $58.5M | $59.4M | $60.2M | $62.3M | $63.9M |
Precio
| Precio | $3.68 |
| Capitalización | $242M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ALT · AURA · DMAC · DRTS · DSGN · ENGN · IMAB
Explorar sector: Healthcare · Biotechnology
Más secciones de GALT: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones